73 results on '"Reiter, Robert E."'
Search Results
2. Stem cells in prostate and prostate cancer development
- Author
-
Lam, John S. and Reiter, Robert E.
- Subjects
- *
STEM cells , *CANCER cells , *PROSTATE cancer , *CELL populations - Abstract
Abstract: Most cancers comprise a heterogenous population of cells with marked differences in their potential to proliferate as well as the ability to reconstitute the tumor upon transplantation. Cancer stem cells are a minor population of tumor cells that possess the stem cell property of self-renewal. Dysregulation of stem cell self-renewal is a likely requirement for the development of cancer. Cell signaling pathways shared by stem cells and cancer cells lend further evidence for a possible link between these 2 populations of cells. Study of the differentiation pathways of normal and abnormal prostate growth has led to the development of a stem cell model for prostate cancer. The basal layer of the normal prostate is believed to be populated by prostate epithelial stem cells and a population of transit-amplifying cells intermediate in differentiation to the stem and fully differentiated cells. There is recent evidence suggesting that prostate cancer occurs from malignant transformation of stem/progenitor cells, thereby resisting apoptosis and spawning proliferation. This new model for prostate cancer will have significant ramifications for the way this disease is studied and treated. Furthermore, through targeting the prostate cancer stem cell and its dysregulated self-renewal, therapies for treatment of prostate cancer are likely to improve. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
3. Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR.
- Author
-
Ong, Wee Loon, Nikitas, John, Joseph, David, Steigler, Allison, Millar, Jeremy, Valle, Luca, Steinberg, Michael L., Ma, Ting Martin, Reiter, Robert E., Rettig, Matthew B., Nickols, Nicholas G., Chang, Albert, Zaorsky, Nicholas G., Spratt, Daniel E., Romero, Tahmineh, and Kishan, Amar U.
- Subjects
- *
EXTERNAL beam radiotherapy , *RADIOTHERAPY , *RADIOISOTOPE brachytherapy , *RADAR , *PROSTATE - Abstract
Adding high-dose-rate brachytherapy (BT) boost to external beam radiation therapy (EBRT) improves biochemical control but may affect patient-reported quality of life (QOL). We sought to determine long-term QOL outcomes for EBRT+BT versus EBRT alone. This was a post hoc analysis of the Trans-Tasman Radiation Oncology Group 03.04 Randomized Androgen Deprivation and Radiotherapy (TROG 03.04 RADAR) trial. Only patients who received 74 Gy conventionally fractionated EBRT (n = 260) or 46 Gy conventionally fractionated EBRT plus 19.5 Gy in 3 fractions high-dose-rate BT boost (n = 237) were included in this analysis. The primary endpoint was patient-reported QOL measured using the European Organisation for Research and Treatment of Cancer QOL (EORTC QLQ-C30) and prostate-specific QOL module (EORTC QLQ-PR25) questionnaires. We evaluated temporal changes in QOL scores, rates of symptom resolution, and the proportion of men who had decrements from baseline of >2 × the threshold for minimal clinically important change (2 × MCIC) for each domain. At 5, 17, and 29 months after radiation therapy, the EBRT+BT group had 2.5 times (95% confidence interval [CI], 1.4-4.2; P <.001), 2.9 times (95% CI, 1.7-4.9; P <.001), and 2.6 times (95% CI, 1.4-4.6; P =.002) greater odds of reporting 2 × MCIC in urinary QOL score compared with EBRT. There were no differences beyond 29 months. EBRT+BT led to a slower rate of urinary QOL symptom score resolution up to 17 months after radiation therapy compared with EBRT (P <.001) but not at later intervals. In contrast, at the end of the radiation therapy period and at 53 months after radiation therapy, the EBRT+BT group had 0.65 times (95% CI, 0.44-0.96; P =.03) and 0.51 times (95% CI, 0.32-0.79; P =.003) the odds of reporting 2 × MCIC in bowel QOL symptom scores compared with EBRT. There were no significant differences in the rate of bowel QOL score resolution. There were no significant differences in global health status or sexual activity scores between the 2 groups. There were no persistent differences in patient-reported QOL measures between EBRT alone and EBRT+BT. BT boost does not appear to negatively affect long-term, patient-reported QOL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer.
- Author
-
Reiter, Robert E., Gu, Zhennen, Watabe, Tetsuro, Thomas, George, Szigeti, Kinga, Davis, Elizabeth, Wahl, Matthew, Nisitani, Sazuku, Yamashiro, Joyce, Le Beau, Michelle M., Loda, Massimo, and Witte, Owen N.
- Subjects
- *
PROSTATE diseases - Abstract
Presents information on the identification of prostate stem cell antigen (PSCA) importance to the development of diagnostic and therapeutic modalities for the management of prostate cancer. Indentification of the PSCA; Background information on prostates cancer; Information on PSCA expression; Methods used in the identification process.
- Published
- 1998
- Full Text
- View/download PDF
5. Adjusting Our Approach to Multiparametric Magnetic Resonance Imaging-based Targeted Prostate Biopsies: Considerations After the FUTURE Trial.
- Author
-
Sadun, Taylor Y. and Reiter, Robert E.
- Subjects
- *
PROSTATE biopsy , *MAGNETIC resonance - Published
- 2019
- Full Text
- View/download PDF
6. INTERNATIONAL VARIATIONS IN QUALITY METRICS FOR LOCALIZED PROSTATE CANCER.
- Author
-
Weiner, Adam B., Nguyen, Anissa V., Reiter, Robert E., and Litwin, Mark S.
- Subjects
- *
PROSTATE cancer , *WATCHFUL waiting , *PROSTATE cancer patients , *RADIONUCLIDE imaging , *CANCER diagnosis , *CANCER patient care , *BONFERRONI correction - Abstract
Adherence to evidence-based guidelines can improve quality of care for patients with prostate cancer. Variation by international region in quality metrics for localized prostate cancer have not been described. The analytic cohort comprised patients diagnosed with local-regional prostate cancer from 2013 to 2022 at one of the participating sites in the 12-country, Movember True North Global Registry. Four primary outcomes indicative of quality care were assessed: 1) Use of active surveillance for low-risk prostate cancer; 2) treatment within 12 months of diagnosis for unfavorable-risk prostate cancer; 3) no use of staging imaging (bone scan, CT, or PET) for imaging favorable-risk prostate cancer; and 4) use of staging imaging for unfavorable-risk prostate cancer. Regional variations in these outcomes were assessed. Primary outcomes were tested using Chi-Square analyses by combining the most recent three years of data entry by region for each outcome, adjusting for multiple tests with the Bonferroni correction (P=0.05/4 = 0.0125). Rates of active surveillance for low-risk prostate cancer in the years 2020-2022 were the highest in Australia/New Zealand (85%) compared to 14% in Central Europe (Figure). Active treatment rates for unfavorable-risk disease within 12 months of diagnosis were highest in Central Europe (98%) compared with 64% in the US. Rates of no imaging for favorable-risk disease ranged from 99% in Central Europe to 30% in Italy while rates of imaging for unfavorable-risk disease ranged from 83% in Hong Kong to 2% for Central Europe (all Chi-Square P<0.0125). This is the first description comparing quality metrics for localized prostate cancer in a single international observational dataset. While quality metrics may vary based on regional cultural and healthcare structures, these benchmarks can promote processes aimed at optimizing management practices. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. The utility of prostate MRI within active surveillance: description of the evidence.
- Author
-
Dominique, Georgina, Brisbane, Wayne G., and Reiter, Robert E.
- Subjects
- *
WATCHFUL waiting , *MAGNETIC resonance imaging , *PROSTATE cancer patients , *PROSTATE - Abstract
Purpose: We present an overview of the literature regarding the use of MRI in active surveillance of prostate cancer. Methods: Both MEDLINE® and Cochrane Library were queried up to May 2020 for studies of men on active surveillance with MRI and later confirmatory biopsy. The terms studied were 'prostate cancer' as the anchor followed by two of the following: active surveillance, surveillance, active monitoring, MRI, NMR, magnetic resonance imaging, MRI, and multiparametric MRI. Studies were excluded if pathologic reclassification (GG1 → ≥ GG2) and PI-RADS or equivalent was not reported. Results: Within active surveillance, baseline MRI is effective for identifying clinically significant prostate cancer and thus associated with fewer reclassification events. A positive initial MRI (≥ PI-RADS 3) with GG1 identified at biopsy has a positive predictive value (PPV) of 35–40% for reclassification by 3 years. MRI possessed a stronger negative predictive value, with a negative MRI (≤ PI-RADS 2) yielding a negative predictive value of up to 85% at 3 years. Surveillance MRI, obtained after initial biopsy, yielded a PPV of 11–65% and NPV of 85–95% for reclassification. Conclusion: MRI is useful for initial risk stratification of prostate cancer in men on active surveillance, especially if MRI is negative when imaging is obtained during surveillance. While useful, MRI cannot replace biopsy and further research is necessary to fully integrate MRI into active surveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Is Targeted Biopsy Applicable to Patients on Active Surveillance?
- Author
-
Prado, Kris and Reiter, Robert E.
- Subjects
- *
PROSTATE biopsy , *DIAGNOSIS , *PROSTATE cancer , *WATCHFUL waiting , *PROSTATE cancer patients , *MEDICAL care - Published
- 2017
- Full Text
- View/download PDF
9. Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
- Author
-
Djaïleb, Loïc, Armstrong, Wesley R., Thompson, Daniel, Gafita, Andrei, Farolfi, Andrea, Rajagopal, Abhejit, Grogan, Tristan R., Nguyen, Kathleen, Benz, Matthias R., Hotta, Masatoshi, Barbato, Francesco, Ceci, Francesco, Schwarzenböck, Sarah M., Unterrainer, Marcus, Zacho, Helle D., Juarez, Roxanna, Cooperberg, Matthew, Carroll, Peter, Washington, Samuel, and Reiter, Robert E.
- Subjects
- *
POSITRON emission tomography , *CLINICAL trials , *RISK assessment , *PROSTATE-specific antigen , *RADICAL prostatectomy , *GLEASON grading system , *LYMPHADENECTOMY - Abstract
The integration of prostate-specific membrane antigen positron emission tomography to the presurgical risk assessment improves the performance and reduces the difference with the postsurgical reference standard for biochemical recurrence–free survival risk assessment of patients with intermediate- to high-risk prostate cancer treated with radical prostatectomy and pelvic lymph node dissection. In the initial staging of patients with high-risk prostate cancer (PCa), prostate-specific membrane antigen positron emission tomography (PSMA-PET) has been established as a front-line imaging modality. The increasing number of PSMA-PET scans performed in the primary staging setting might be associated with decreases in biochemical recurrence (BCR)-free survival (BCR-FS). To assess the added prognostic value of presurgical PSMA-PET for BCR-FS compared with the presurgical Cancer of the Prostate Risk Assessment (CAPRA) and postsurgical CAPRA-Surgery (CAPRA-S) scores in patients with intermediate- to high-risk PCa treated with radical prostatectomy (RP) and pelvic lymph node dissection. This is a follow-up study of the surgical cohort evaluated in the multicenter prospective phase 3 imaging trial (n = 277; NCT03368547, NCT02611882, and NCT02919111). Each 68Ga-PSMA-11-PET scan was read by three blinded independent readers. PSMA-PET prostate uptake (low vs high), PSMA-PET extraprostatic disease (N1/M1), and CAPRA and CAPRA-S scores were used to assess the risk of BCR. Patients were followed after RP by local investigators using electronic medical records. BCR was defined by a prostate-specific antigen (PSA) level increasing to ≥0.2 ng/ml after RP or initiation of PCa-specific secondary treatment (>6 mo after surgery). Univariate and multivariable Cox models, and c-statistic index were performed to assess the prognostic value of PSMA-PET and for a comparison with the CAPRA and CAPRA-S scores. From December 2015 to December 2019, 277 patients underwent surgery after PSMA-PET. Clinical follow-up was obtained in 240/277 (87%) patients. The median follow-up after surgery was 32.4 (interquartile range 23.3–42.9) mo. Of 240 BCR events, 91 (38%) were observed. PSMA-PET N1/M1 was found in 41/240 (17%) patients. PSMA-PET prostate uptake, PSMA-PET N1/M1, and CAPRA and CAPRA-S scores were significant univariate predictors of BCR. The addition of PSMA-PET N1/M1 status to the presurgical CAPRA score improved the risk assessment for BCR significantly in comparison with the presurgical CAPRA score alone (c-statistic 0.70 [0.64–0.75] vs 0.63 [0.57–0.69]; p < 0.001). The C-index of the postsurgical model utilizing the postsurgical CAPRA-S score alone was not significantly different from the presurgical model combining the presurgical CAPRA score and PSMA-PET N1/M1 status (p = 0.19). Presurgical PSMA-PET was a strong prognostic biomarker improving BCR-FS risk assessment. Its implementation in the presurgical risk assessment with the CAPRA score improved the performance and reduced the difference with the reference standard (postsurgical CAPRA-S score). The use prostate-specific membrane antigen positron emission tomography improved the assessment of biochemical recurrence risk in patients with intermediate- and high-risk prostate cancer who were treated with radical prostatectomy and pelvic lymph node dissection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Hormonal Therapy for Men Undergoing Definitive Radiation for Prostate Cancer.
- Author
-
Valle, Luca F., Kishan, Amar U., and Reiter, Robert E.
- Subjects
- *
RADIOTHERAPY , *HORMONE therapy , *PROSTATE cancer , *CLINICAL trials , *ANDROGEN deprivation therapy , *PATIENT selection - Published
- 2023
11. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials.
- Author
-
Smith, Clayton P., Xiang, Michael, Armstrong, Wesley R., Nickols, Nicholas G., Steinberg, Michael L., Reiter, Robert E., Rettig, Matthew, Weiner, Adam B., Shen, John, Valle, Luca, Czernin, Johannes, Calais, Jeremie, and Kishan, Amar U.
- Subjects
- *
POSITRON emission tomography , *COMPUTED tomography , *PROSTATE cancer patients , *GALLIUM - Published
- 2023
- Full Text
- View/download PDF
12. Risk stratification of prostate cancer 2016.
- Author
-
Reiter, Robert E.
- Subjects
- *
PROSTATE cancer , *CANCER in men , *PROSTATE cancer risk factors , *RISK assessment , *METASTASIS , *DIAGNOSTIC use of tumor markers , *ANTINEOPLASTIC agents , *BIOPSY , *CELL receptors , *GENES , *PROGNOSIS , *TUMOR antigens , *PROSTATE tumors , *PROSTATE-specific antigen , *TREATMENT effectiveness , *EARLY diagnosis , *TUMOR grading , *DIAGNOSIS - Abstract
Prostate cancer is a common malignancy in men, but its management is fraught with controversy owing to its variable biologic and clinical behavior. Despite evidence that PSA screening reduces prostate cancer specific metastasis and death, it has not gained acceptance by various health authorities. Nevertheless, recent advances in biomarker development potentially address many of the shortcomings of routine PSA testing alone, including improved specificity for the detection of clinically significant cancer, optimized risk stratification to aid clinical management decisions, and discovery of genetic variants that may guide optimized therapy of advanced disease. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
13. The urologist role in basic and clinical translational research: Personal reflections of a urologic scientist
- Author
-
Reiter, Robert E.
- Published
- 2009
- Full Text
- View/download PDF
14. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
- Author
-
Weiner, Adam B., Liu, Yang, Hakansson, Alex, Zhao, Xin, Proudfoot, James A., Ho, Julian, Zhang, JJ H., Li, Eric V., Karnes, R. Jeffrey, Den, Robert B., Kishan, Amar U., Reiter, Robert E., Hamid, Anis A., Ross, Ashely E., Tran, Phuoc T., Davicioni, Elai, Spratt, Daniel E., Attard, Gerhardt, Lotan, Tamara L., and Lee Kiang Chua, Melvin
- Subjects
- *
PROSTATE cancer , *ANDROGEN receptors , *GENE expression profiling , *CLINICAL trials , *PROSTATE tumors , *GENE expression - Abstract
Background: Prostate cancer (PCa) is a clinically heterogeneous disease. The creation of an expression‐based subtyping model based on prostate‐specific biological processes was sought. Methods: Unsupervised machine learning of gene expression profiles from prospectively collected primary prostate tumors (training, n = 32,000; evaluation, n = 68,547) was used to create a prostate subtyping classifier (PSC) based on basal versus luminal cell expression patterns and other gene signatures relevant to PCa biology. Subtype molecular pathways and clinical characteristics were explored in five other clinical cohorts. Results: Clustering derived four subtypes: luminal differentiated (LD), luminal proliferating (LP), basal immune (BI), and basal neuroendocrine (BN). LP and LD tumors both had higher androgen receptor activity. LP tumors also had a higher expression of cell proliferation genes, MYC activity, and characteristics of homologous recombination deficiency. BI tumors possessed significant interferon γactivity and immune infiltration on immunohistochemistry. BN tumors were characterized by lower androgen receptor activity expression, lower immune infiltration, and enrichment with neuroendocrine expression patterns. Patients with LD tumors had less aggressive tumor characteristics and the longest time to metastasis after surgery. Only patients with BI tumors derived benefit from radiotherapy after surgery in terms of time to metastasis (hazard ratio [HR], 0.09; 95% CI, 0.01–0.71; n = 855). In a phase 3 trial that randomized patients with metastatic PCa to androgen deprivation with or without docetaxel (n = 108), only patients with LP tumors derived survival benefit from docetaxel (HR, 0.21; 95% CI, 0.09–0.51). Conclusions: With the use of expression profiles from over 100,000 tumors, a PSC was developed that identified four subtypes with distinct biological and clinical features. Plain language summary: Prostate cancer can behave in an indolent or aggressive manner and vary in how it responds to certain treatments.To differentiate prostate cancer on the basis of biological features, we developed a novel RNA signature by using data from over 100,000 prostate tumors—the largest data set of its kind.This signature can inform patients and physicians on tumor aggressiveness and susceptibilities to treatments to help personalize cancer management. Data from over 100,000 prostate tumors and multiple cohorts were used to create and validate an expression‐based signature that can subtype prostate cancer on the basis of biological features and treatment susceptibilities. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. LUNAR: a randomized Phase 2 study of 177Lutetium‐PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol).
- Author
-
Ma, Ting Martin, Czernin, Johannes, Felix, Carol, Alano, Rejah, Wilhalme, Holly, Valle, Luca, Steinberg, Michael L., Dahlbom, Magnus, Reiter, Robert E., Rettig, Matthew B., Cao, Minsong, Calais, Jeremie, and Kishan, Amar U.
- Subjects
- *
PROSTATE cancer , *LUNAR phases , *MEDICAL protocols , *POSITRON emission tomography , *ANDROGEN deprivation therapy , *STEREOTACTIC radiotherapy - Abstract
Objective: To assess the efficacy of 177Lu‐PNT2002, a novel radiolabelled small molecule that binds with high affinity to prostate‐specific membrane antigen (PSMA), in combination with stereotactic body radiotherapy (SBRT) to all sites of metastasis, vs SBRT alone, in men with oligorecurrent metastatic hormone‐sensitive prostate cancer (mHSPC). Patients and Methods: The 177Lutetium‐PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR) trial is an open‐label, randomized, stratified, two‐arm, single‐centre, Phase 2 trial to compare the efficacy and safety of neoadjuvant 177Lu‐PNT2002 plus SBRT vs SBRT alone in men with oligorecurrent mHSPC. Key eligibility criteria include one to five lesions identified on a PSMA positron emission tomography (PET)/computed tomography (CT) scan centrally reviewed by a board‐certified nuclear medicine physician. Key exclusion criteria include castrate‐resistant disease, de novo oligometastatic disease and receipt of androgen deprivation therapy (ADT) within 6 months of trial enrolment. The trial aims to enrol 100 patients who will be centrally randomized to one of the two treatment arms, in a 1:1 ratio. Patients in the control arm receive SBRT to all sites of disease. Patients in the experimental arm receive two cycles of neoadjuvant 177Lu‐PNT2002 (6.8 GBq) 6–8 weeks apart, followed by an interval PSMA PET/CT in 4–6 weeks and dose‐adapted SBRT to all sites of disease 1–2 weeks later. The primary endpoint is progression‐free survival. Secondary endpoints are radiographic and prostate‐specific antigen‐based progression, acute and late physician‐scored toxicity, patient‐reported quality of life, ADT‐free survival, time to progression, overall survival, locoregional control, and duration of response. Enrolment in the study commenced in September 2022. Results and Conclusions: The addition of 177Lu‐PNT2002 to metastasis‐directed therapy alone may potentially further forestall disease progression. The results of this Phase 2 trial will determine, for the first time in a randomized fashion, the added benefit of 177Lu‐PNT2002 to SBRT in patients with oligorecurrent mHSPC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.
- Author
-
Ma, Ting Martin, Ballas, Leslie K., Wilhalme, Holly, Sachdeva, Ankush, Chong, Natalie, Sharma, Sahil, Yang, Tiffany, Basehart, Vincent, Reiter, Robert E., Saigal, Christopher, Chamie, Karim, Litwin, Mark S., Rettig, Matthew B., Nickols, Nicholas G., Yoon, Stephanie M., Smith, Lauren, Gao, Yu, Steinberg, Michael L., Cao, Minsong, and Kishan, Amar U.
- Subjects
- *
RADIOTHERAPY , *PROSTATE cancer patients , *RADICAL prostatectomy , *MAGNETIC resonance imaging , *QUALITY of life , *PROSTATE-specific antigen - Abstract
Postoperative radiation therapy (RT) is an underused standard-of-care intervention for patients with prostate cancer and recurrence/adverse pathologic features after radical prostatectomy. Although stereotactic body RT (SBRT) is a well-studied and convenient option for definitive treatment, data on the postprostatectomy setting are extremely limited. The purpose of this study was to evaluate short-term physician-scored genitourinary (GU) and gastrointestinal (GI) toxicities and patient-reported outcomes after postprostatectomy SBRT. The SCIMITAR trial was a phase 2, dual-center, open-label, single-arm trial that enrolled patients with postoperative prostate-specific antigen >0.03 ng/mL or adverse pathologic features. Coprimary endpoints were 4-year biochemical recurrence–free survival, physician-scored acute and late GU and GI toxicities by the Common Terminology Criteria for Adverse Events (version 4.03) scale, and patient-reported quality-of-life (QOL) outcomes, as represented by the Expanded Prostate Cancer Index-26 and the International Prostate Symptom Score. Patients received SBRT 30 to 34 Gy/5 fractions to the prostate bed ± bed boost ± pelvic nodes with computed tomography (CTgRT) or magnetic resonance imaging guidance (MRgRT) in a nonrandomized fashion. Physician-scored toxicities and patient-reported QOL outcomes were collected at baseline and at 1, 3, and 6 months of follow-up. Univariable and multivariable analyses were performed to evaluate predictors of toxicities and QOL outcomes. One hundred participants were enrolled (CTgRT, n = 69; MRgRT, n = 31). The median follow-up was 29.5 months (CTgRT: 33.3 months, MRgRT: 22.6 months). The median (range) prostate bed dose was 32 (30-34) Gy. Acute and late grade 2 GU toxicities were both 9% while acute and late grade 2 GI toxicities were 5% and 0%, respectively. Three patients had grade 3 toxicity (n = 1 GU, n = 2 GI). No patient receiving MRgRT had grade 3 GU or grade ≥2 GI toxicity. Compared with CTgRT, MRgRT was associated with a 30.5% (95% confidence interval, 11.6%-49.5%) reduction in any-grade acute GI toxicity (P =.006). MRgRT was independently associated with improved any-grade GI toxicity and improved bowel QOL. Postprostatectomy SBRT was well tolerated at short-term follow-up. MRgRT may decrease GI toxicity. Longer toxicity and/or efficacy follow-up and randomized studies are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Controversies in urologic oncology
- Author
-
Reiter, Robert E.
- Published
- 2007
- Full Text
- View/download PDF
18. Translational advances in urologic cancer
- Author
-
Reiter, Robert E.
- Published
- 2007
- Full Text
- View/download PDF
19. Fundamental advances in the biology of urologic cancer
- Author
-
Reiter, Robert E.
- Published
- 2007
- Full Text
- View/download PDF
20. Biological, translational, and clinical advances in urologic oncology: Sessions of the Society of Urologic Oncology annual meeting, Atlanta, GA, May 2006
- Author
-
Reiter, Robert E.
- Published
- 2007
- Full Text
- View/download PDF
21. Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena.
- Author
-
Khoo, Amanda, Liu, Lydia Y., Sadun, Taylor Y., Salmasi, Amirali, Pooli, Aydin, Felker, Ely, Houlahan, Kathleen E., Ignatchenko, Vladimir, Raman, Steven S., Sisk Jr., Anthony E., Reiter, Robert E., Boutros, Paul C., and Kislinger, Thomas
- Subjects
- *
MAGNETIC resonance imaging , *PROSTATE cancer , *PROSTATE - Abstract
Multiparametric magnetic resonance imaging (mpMRI) is an emerging standard for diagnosing and prognosing prostate cancer, but ~ 20% of clinically significant tumors are invisible to mpMRI, as defined by the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) score of one or two. To understand the biological underpinnings of tumor visibility on mpMRI, we examined the proteomes of forty clinically significant tumors (i.e., International Society of Urological Pathology (ISUP) Grade Group 2)—twenty mpMRI-visible and twenty mpMRI-invisible, with matched histologically normal prostate. Normal prostate tissue was indistinguishable between patients with visible and invisible tumors, and invisible tumors closely resembled the normal prostate. These data indicate that mpMRI-visibility arises when tumor evolution leads to large-magnitude proteomic divergences from histologically normal prostate. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status
- Author
-
Fondrevelle, Marie E., Kantelip, Bernadette, Reiter, Robert E., Chopin, Dominique K., Thiery, Jean P., Monnien, Franck, Bittard, Hugues, and Wallerand, Hervé
- Subjects
- *
CANCER patients , *BLADDER , *IMMUNOHISTOCHEMISTRY , *CIGARETTE smokers - Abstract
Abstract: Objectives: Twist is considered as transcription factor that regulates epithelial mesenchymal transition (EMT) by at least inhibition of E-cadherin expression. EMT is a key event in the tumor invasion process. The purpose of this study is to investigate the expression of Twist but also those of E- and N-cadherin in human primary bladder tumor and to evaluate its prognostic value. As smoking cigarettes is a strong bladder cancer risk factor, we tried to evaluate the impact of the tobacco status on these molecular abnormalities. Materials and Methods: To delineate on the oncogenic role for Twist in human bladder cancer, we evaluated the E- and N-cadherin but also Twist expression (n = 70) by immunohistochemistry. We evaluated the prognostic value of these expressions. Moreover, we tried to correlate these protein expressions to the smoking status of the patients. Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis. Results: Of the 70 bladder tumors, 28 (40%) cases were positive for Twist expression, 16 (23%) cases were negative for E-cadherin expression, and 12 (17%) were positive for N-cadherin expression. When categorized into negative vs. positive expression, Twist was associated with the stage (P = 0.001), the grade (P < 0.001), the progression (P = 0.02), and the E-cadherin expression (P = 0.01). Moreover, positive Twist expression clearly predicted poorer PFS (P = 0.02). In the multivariate analysis, both positive Twist expression and loss of E-cadherin expression were independent prognostic factors for PFS (P = 0.046 and P = 0.001, respectively) and only loss of E-cadherin expression for the OS (P < 0.001). We also demonstrated that almost 60% (16/28) of patients with Twist-positive expression were current smokers at the time of the diagnosis, corroborating the fact that smoking modulates the expression of EMT markers including Twist. Conclusion: Positive Twist expression may be a useful prognostic marker for patients with bladder cancer. Its expression seems to be correlated to the tobacco status of the patients. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
23. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).
- Author
-
Valle, Luca F., Lehrer, Eric J., Markovic, Daniela, Elashoff, David, Levin-Epstein, Rebecca, Karnes, R. Jeffery, Reiter, Robert E., Rettig, Matthew, Calais, Jeremie, Nickols, Nicholas G., Dess, Robert T., Spratt, Daniel E., Steinberg, Michael L., Nguyen, Paul L., Davis, Brian J., Zaorsky, Nicholas G., and Kishan, Amar U.
- Subjects
- *
PROSTATE cancer , *HIGH-intensity focused ultrasound , *RADICAL prostatectomy , *SALVAGE therapy , *HIGH dose rate brachytherapy , *LOW dose rate brachytherapy - Abstract
Management of locally recurrent prostate cancer after definitive radiotherapy remains controversial due to the perceived high rates of severe genitourinary (GU) and gastrointestinal (GI) toxicity associated with any local salvage modality. To quantitatively compare the efficacy and toxicity of salvage radical prostatectomy (RP), high-intensity focused ultrasound (HIFU), cryotherapy, stereotactic body radiotherapy (SBRT), low–dose-rate (LDR) brachytherapy, and high-dose-rate (HDR) brachytherapy. We performed a systematic review of PubMed, EMBASE, and MEDLINE. Two- and 5-yr recurrence-free survival (RFS) rates and crude incidences of severe GU and GI toxicity were extracted as endpoints of interest. Random-effect meta-analyses were conducted to characterize summary effect sizes and quantify heterogeneity. Estimates for each modality were then compared with RP after adjusting for individual study-level covariates using mixed-effect regression models, while allowing for differences in between-study variance across treatment modalities. A total of 150 studies were included for analysis. There was significant heterogeneity between studies within each modality, and covariates differed between modalities, necessitating adjustment. Adjusted 5-yr RFS ranged from 50% after cryotherapy to 60% after HDR brachytherapy and SBRT, with no significant differences between any modality and RP. Severe GU toxicity was significantly lower with all three forms of radiotherapeutic salvage than with RP (adjusted rates of 20% after RP vs 5.6%, 9.6%, and 9.1% after SBRT, HDR brachytherapy, and LDR brachytherapy, respectively; p ≤ 0.001 for all). Severe GI toxicity was significantly lower with HDR salvage than with RP (adjusted rates 1.8% vs 0.0%, p < 0.01), with no other differences identified. Large differences in 5-yr outcomes were not uncovered when comparing all salvage treatment modalities against RP. Reirradiation with SBRT, HDR brachytherapy, or LDR brachytherapy appears to result in less severe GU toxicity than RP, and reirradiation with HDR brachytherapy yields less severe GI toxicity than RP. Prospective studies of local salvage for radiorecurrent disease are warranted. In a large study-level meta-analysis, we looked at treatment outcomes and toxicity for men treated with a number of salvage treatments for radiorecurrent prostate cancer. We conclude that relapse-free survival at 5 years is equivalent among salvage modalities, but reirradiation may lead to lower toxicity. This meta-analysis provides pooled estimates of surgical and nonsurgical local salvage treatments for radiorecurrent prostate cancer. Five-year recurrence-free survival (RFS) was similar across modalities on meta-regression, although differences in severe genitourinary and gastrointestinal toxicity appear to favor reirradiation, particularly high-dose-rate brachytherapy. Pretreatment prostate-specific antigen emerged as a powerful predictor of 5-yr RFS. Additional prospective and randomized data are required to better define how to optimally select and treat patients with isolated local failures after definitive radiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.
- Author
-
Fendler, Wolfgang P., Calais, Jeremie, Eiber, Matthias, Simko, Jeffrey P., Kurhanewicz, John, Santos, Romelyn Delos, Feng, Felix Y., Reiter, Robert E., Rettig, Matthew B., Nickols, Nicholas G., Kishan, Amar U., PSMA PET Reader Group, Shozo, Okamoto, Emmett, Louise, Zacho, Helle D., Ilhan, Harun, Rischpler, Christoph, Wetter, Axel, Schoder, Heiko, and Burger, Irene A.
- Subjects
- *
PROSTATE , *HOSPITAL central service departments , *PROSTATE cancer , *TREATMENT effectiveness , *EXOCRINE glands - Abstract
Purpose: Readers need to be informed about potential pitfalls of [68Ga]Ga-PSMA-11 PET interpretation. Methods: Here we report [68Ga]Ga-PSMA-11 PET findings discordant with the histopathology/composite reference standard in a recently published prospective trial on 635 patients with biochemically recurrent prostate cancer. Results: Consensus reads were false positive in 20 regions of 17/217 (8%) patients with lesion validation. Majority of the false positive interpretations (13 of 20, 65%) occurred in the context of suspected prostate (bed) relapse (T) after radiotherapy (n = 11); other false positive findings were noted for prostate bed post prostatectomy (T, n = 2), pelvic nodes (N, n = 2), or extra pelvic lesions (M, n = 5). Major sources of false positive findings were PSMA-expressing residual adenocarcinoma with marked post-radiotherapy treatment effect. False negative interpretation occurred in 8 regions of 6/79 (8%) patients with histopathology validation, including prostate (bed) (n = 5), pelvic nodes (n = 1), and extra pelvic lesions (n = 2). Lesions were missed mostly due to small metastases or adjacent bladder/urine uptake. Conclusion: [68Ga]Ga-PSMA-11 PET at biochemical recurrence resulted in less than 10% false positive interpretations. Post-radiotherapy prostate uptake was a major source of [68Ga]Ga-PSMA-11 PET false positivity. In few cases, PET correctly detects residual PSMA expression post-radiotherapy, originating however from treated, benign tissue or potentially indolent tumor remnants. Trial registration number: ClinicalTrials.gov Identifiers: NCT02940262 and NCT03353740. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
- Author
-
Parikh, Neil R., Chang, Eric M., Nickols, Nicholas G., Rettig, Matthew B., Raldow, Ann C., Steinberg, Michael L., Koontz, Bridget F., Vapiwala, Neha, Deville, Curtiland, Feng, Felix Y., Spratt, Daniel E., Reiter, Robert E., Phillips, Ryan, Ost, Piet, Tran, Phuoc T., and Kishan, Amar U.
- Subjects
- *
PROSTATE cancer , *ABIRATERONE acetate , *CASTRATION-resistant prostate cancer , *MONTE Carlo method , *COST effectiveness , *DOCETAXEL , *THERAPEUTIC use of antineoplastic agents , *STEROID drugs , *RESEARCH , *CONFIDENCE intervals , *ANTIANDROGENS , *TIME , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *SYSTEM analysis , *RESEARCH funding , *RADIOSURGERY , *SALVAGE therapy , *PREDNISONE , *PROSTATE tumors , *QUALITY-adjusted life years , *PROBABILITY theory - Abstract
Purpose: Oligorecurrent prostate cancer has historically been treated with indefinite androgen deprivation therapy (ADT), although many patients and providers opt to defer this treatment at the time of recurrence given quality-of-life and/or comorbidity considerations. Recently, metastasis-directed therapy (MDT) has emerged as a potential intermediary between surveillance and immediate continuous ADT. Simultaneously, advanced systemic therapy in addition to ADT has also been shown to improve survival in metastatic hormone-sensitive disease. This study aimed to compare the cost-effectiveness of treating oligorecurrent patients with upfront MDT before standard-of-care systemic therapy.Methods and Materials: A Markov-based cost-effectiveness analysis was constructed comparing 3 strategies: (1) upfront MDT → salvage abiraterone acetate plus prednisone (AAP) + ADT → salvage docetaxel + ADT; (2) upfront AAP + ADT → salvage docetaxel + ADT; and (3) upfront docetaxel + ADT → salvage AAP + ADT. Transition probabilities and utilities were derived from the literature. Using a 10-year time horizon and willingness-to-pay threshold of $100,000/quality-adjusted life year (QALY), net monetary benefit values were subsequently calculated for each treatment strategy.Results: At 10 years, the base case revealed a total cost of $141,148, $166,807, and $136,154 with QALYs of 4.63, 4.89, and 4.00, respectively, reflecting a net monetary benefit of $322,240, $322,018, and $263,407 for upfront MDT, upfront AAP + ADT, and upfront docetaxel + ADT, respectively. In the probabilistic sensitivity analysis using a Monte Carlo simulation (1,000,000 simulations), upfront MDT was the cost-effective strategy in 53.6% of simulations. The probabilistic sensitivity analysis revealed 95% confidence intervals for cost ($75,914-$179,862, $124,431-$223,892, and $103,298-$180,617) and utility in QALYs (3.85-6.12, 3.91-5.86, and 3.02-5.22) for upfront MDT, upfront AAP + ADT, and upfront docetaxel + ADT, respectively.Conclusions: At 10 years, upfront MDT followed by salvage AAP + ADT, is comparably cost-effective compared with upfront standard-of-care systemic therapy and may be considered a viable treatment strategy, especially in patients wishing to defer systemic therapy for quality-of-life or comorbidity concerns. Additional studies are needed to determine whether MDT causes a sustained meaningful delay in disease natural history and whether any benefit exists in combining MDT with upfront advanced systemic therapy. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
26. Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer.
- Author
-
Tsai, Wen-Ting K, Zettlitz, Kirstin A, Dahlbom, Magnus, Reiter, Robert E, and Wu, Anna M
- Subjects
- *
RADIOIMMUNOTHERAPY , *ANIMAL models in research , *PROSTATE cancer , *TUMOR growth , *STEM cells , *CYTOTOXIC T cells - Abstract
Purpose: Radioimmunotherapy uses tumor-specific antibodies to deliver therapeutic radionuclides, but hematological toxicity due to the long serum half-life of intact antibodies remains a challenge. We evaluated a smaller antibody fragment, the minibody, with faster kinetics and a potentially improved therapeutic index. Procedures: The anti-prostate stem cell antigen (PSCA) minibody (A11 Mb) was radiolabeled with iodine-124 ([124I]I-A11 Mb) or conjugated with deferoxamine (DFO) and labeled with zirconium-89 ([89Zr]Zr-DFO-A11 Mb) for surrogate immunoPET to profile pharmacokinetics in a human prostate cancer xenograft model. Subsequently, minibodies labeled with two therapeutic beta emitters, directly iodinated [131I]I-A11 Mb (non-residualizing) and 177Lu chelated using DTPA ([177Lu]Lu-DTPA-A11 Mb) (residualizing), were compared for in vitro antigen-specific cytotoxicity. Full biodistribution studies (in 22Rv1-PSCA tumor bearing and hPSCA knock-in mice) were conducted for dosimetry calculations. Finally, the lead candidate [131I]I-A11 Mb was evaluated in a radioimmunotherapy experiment. Escalating single doses (3.7, 11, or 37 MBq) and saline control were administered to 22Rv1-PSCA tumor bearing mice and anti-tumor effects (tumor volume) and toxicity (body weight) were monitored. Results: Minibodies radiolabeled with therapeutic beta emitters [131I]I-A11 Mb and [177Lu]Lu-DTPA-A11 Mb exhibited comparable tumor cell growth inhibition in vitro. In vivo surrogate immunoPET imaging using [89Zr]Zr-DFO-A11 Mb showed activity retention in liver and kidney up to 72 h, while [124I]I-A11 Mb cleared from liver, kidney, and blood by 48 h. Based on full biodistribution and dosimetry calculations, administering 37 MBq [131I]I-A11 Mb was predicted to deliver a favorable dose to the tumor (35 Gy), with a therapeutic index of 22 (tumor:bone marrow). For [177Lu]Lu-DTPA-A11 Mb, the kidneys would be dose-limiting, and the maximum tolerated activity (7.4 MBq) was not predicted to deliver an effective radiation dose to tumor. Radioimmunotherapy with a single dose of [131I]I-A11 Mb showed dose-dependent tumor inhibition with minimal off-target toxicity and improved median survival (19 and 24 days, P < 0.001) compared with untreated mice (12 days). Conclusions: These findings show the potential of the anti-PSCA minibody for targeted radioimmunotherapy with minimal toxicity, and the application of immunoPET and dosimetry for personalized treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer.
- Author
-
Kishan, Amar U., Romero, Tahmineh, Alshalalfa, Mohammed, Liu, Yang, Tran, Phuoc T., Nickols, Nicholas G., Ye, Huihui, Sajed, Dipti, Rettig, Matthew B., Reiter, Robert E., Garraway, Isla P., Spratt, Daniel E., Freedland, Steven J., Zhao, Xin, Li, Ziwen, Deek, Matthew, Livingstone, Julie, Mahal, Brandon A., Nguyen, Paul L., and Feng, Felix Y.
- Subjects
- *
DNA repair , *GENE expression , *HETEROGENEITY , *CELL cycle , *GLEASON grading system - Abstract
Gleason grade group (GG) 5 prostate cancer has been associated with an aggressive natural history, and retrospective data support a role for treatment intensification. However, clinical outcomes remain heterogeneous in this cohort, and intensified treatments carry an increased risk of adverse events. We sought to explore the transcriptomic heterogeneity of GG 5 tumors by querying transcriptomic data from the tumors of 2138 patients with GG 5 disease who underwent prostatectomy. Four distinct consensus clusters were identified with respect to differential transcriptional activation of hallmark pathways, with distinct molecular subtyping profiles and different average genomic risks (AGRs). One cluster, accounting for 325 tumors (15.2% of the population), was enriched for genes related to the cell cycle/proliferation, metabolic pathways, androgen response pathways, and DNA repair, and had a higher AGR than the other clusters (p < 0.001). This clustering, with an identification of a high genomic risk cluster, was subsequently validated in a separate cohort of 1921 patients as well as a third cohort of 201 patients. The latter cohort had outcomes available, and it was found that patients in the high genomic risk cluster had significantly worse distant metastasis-free survival than the other clusters. Tumors in this high genomic risk cluster of GG 5 disease may be particularly likely to benefit from treatment intensification. In this report, we examined differences in gene expression in tumors from men with Gleason grade group 5 prostate cancer. We identified significant diversity, with one specific subgroup of tumors associated with expression profiles that suggest a worse prognosis. Using transcriptomic data from a large cohort of men treated with radical prostatectomy for Gleason grade group 5 prostate cancer, we identified four distinct clusters of patients based on transcriptional activation of different hallmark pathways. This clustering was replicated in two additional datasets, including one with long-term clinical outcomes. In the latter, patients in one cluster were found to be at a particularly high risk of distant metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Dynamic contrast-enhanced (DCE) MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2.
- Author
-
Afshari Mirak, Sohrab, Mohammadian Bajgiran, Amirhossein, Sung, Kyunghyun, Asvadi, Nazanin H., Markovic, Daniela, Felker, Ely R., Lu, David, Sisk, Anthony, Reiter, Robert E., and Raman, Steven S.
- Subjects
- *
GLEASON grading system , *PROSTATE tumors , *MAGNETIC resonance imaging , *CONTRAST-enhanced magnetic resonance imaging , *PHARMACOKINETICS , *PROSTATE cancer - Abstract
Purpose: To investigate the role of qualitative and quantitative DCE-MRI parameters in prostate cancer (PCa) stratified by whole-mount histopathology (WMHP) Gleason score (GS) and PI-RADSv2. Methods: This retrospective study included 323 PCa tumors in 254 men, who underwent 3T MRI prior to prostatectomy, 7/2009-12/2016. Qualitative DCE curve types included type 1 (progressive), type 2 (plateau) and type 3 (washout). Quantitative DCE-MRI pharmacokinetic (PK) parameters included Ktrans (influx volume transfer coefficient), Kep (efflux reflux rate constant) and iAUC (initial area under the curve). DCE-MRI features of true positive lesions were evaluated for overall, index, transition zone (TZ) and peripheral zone (PZ), based on GS grade (low = 6, high > 6) and PI-RADSv2 score using SPSSv24. Results: There were 57 (17.6%) low-grade and 266 (82.4%) high-grade PCa lesions. PI-RADSv2 3, 4 and 5 included 106, 120 and 97 lesions, respectively. 251 (77.7%) and 72 (22.3%) lesions were located in PZ and TZ, respectively. High-grade lesions had significantly higher proportion of Type 3 curves compared to low-grade lesions in overall (70.3% vs. 54.4%) and TZ (73.5% vs. 43.5%). As PI-RADSv2 increased, the proportion of type 3 curve significantly increased for overall (80.4–51.9%), index (80.4–54.7%) and PZ (78.7–52.1%) lesions. Among PK parameters, Ktrans (0.43 vs 0.32) and iAUC (8.99 vs 6.9) for overall PCa, Ktrans (0.43 vs 0.31) and iAUC (9 vs 6.67) for PZ PCa, and iAUC (8.94 vs 7.42) for index PCa were significantly higher for high-grade versus low-grade lesions. Also, Ktrans (0.51–0.34), Kep (1.75–1.29) and iAUC (9.79–7.6) for overall PCa, Ktrans (0.53–0.32), Kep (1.81–1.26) and iAUC (9.83–7.34) for PZ PCa; and Kep (1.79–1.17) and iAUC (11.3–8.45) for index PCa increased significantly with a higher PI-RADSv2 score. Conclusions: The results of study show the possible utility of qualitative and quantitative DCE-MRI parameters for assessment of PCa GS and PI-RADSv2 categorization. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. [89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model.
- Author
-
Zettlitz, Kirstin A., Tsai, Wen-Ting K., Knowles, Scott M., Salazar, Felix B., Kobayashi, Naoko, Reiter, Robert E., and Wu, Anna M.
- Subjects
- *
HUMAN stem cells , *PROSTATE cancer , *ORGANS (Anatomy) , *PELVIS , *EXOCRINE glands , *POSITRON emission tomography , *ANTIGENS , *ANIMAL experimentation , *RESEARCH funding - Abstract
Purpose: A great challenge in the diagnosis and treatment of prostate cancer is distinguishing between indolent or local disease and aggressive or metastatic disease. Antibody-based positron emission tomography (immuno-PET) as a cancer-specific imaging modality could improve diagnosis of primary disease, aid the detection of metastases to regional lymph nodes as well as to distant sites (e.g., bone), and monitor response to therapy.Procedure: In search for a more physiologically relevant disease model, a human prostate stem cell antigen knock-in (hPSCA KI) mouse model was generated. The use of a syngeneic prostate cancer cell line transduced to express human PSCA (RM-9-hPSCA) enabled the evaluation of anti-PSCA immuno-PET in immunocompetent mice and in the context of normal tissue expression of PSCA. Two PSCA-specific humanized antibody fragments, A11 minibody and A2 cys-diabody, were radiolabeled with positron emitters iodine-124 and zirconium-89, respectively ([124I]A11 Mb and [89Zr]A2cDb), and used for immuno-PET in wild-type, hPSCA KI and tumor-bearing mice.Results: The hPSCA KI mice express PSCA at low levels in the normal prostate, bladder and stomach, reproducing the expression pattern seen in humans. [124I]A11 Mb immuno-PET detected increased levels of PSCA expression in the stomach, and because I-124 is non-residualizing, very little activity was seen in organs of clearance (liver, kidney, spleen). However, due to the longer half-life of the 80 kDa protein, blood activity (and thus urine activity) at 20 h postinjection remains high. The smaller 50 kDa [89Zr]A2cDb cleared faster, resulting in lower blood and background activity, despite the use of a residualizing radiometal. Importantly, [89Zr]A2cDb immuno-PET showed antigen-specific targeting of PSCA-expressing tumors and minimal nonspecific uptake in PSCA-negative controls.Conclusion: Tracer biodistribution was not significantly impacted by normal tissue expression of PSCA. [89Zr]A2cDb immuno-PET yielded high tumor-to-blood ratio at early time points. Rapid renal clearance of the 50 kDa tracer resulted in an unobstructed view of the pelvic region at 20 h postinjection that would allow the detection of cancer in the prostate. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
30. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.
- Author
-
Kishan, Amar U., Chu, Fang-I, King, Christopher R., Seiferheld, Wendy, Spratt, Daniel E., Tran, Phuoc, Wang, Xiaoyan, Pugh, Stephanie E., Sandler, Kiri A., Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Nickols, Nicholas G., Rettig, Matthew, Drakaki, Alexandra, Liu, Sandy T., Reiter, Robert E., Chang, Albert J., Feng, Felix Y., and Sajed, Dipti
- Subjects
- *
PROSTATE cancer , *PROPORTIONAL hazards models , *META-analysis - Abstract
The importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown. To evaluate the clinical implications of LF after definitive RT. Individual patient data meta-analysis of 992 patients (593 Gleason grade group [GG] 4 and 399 GG 5) enrolled in six randomized clinical trials. Multivariable Cox proportional hazard models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), and distant metastasis (DM)-free survival (DMFS) and LF as a time-dependent covariate. Markov proportional hazard models were developed to evaluate the impact of specific transitions between disease states on these endpoints. Median follow-up was 6.4 yr overall and 7.2 yr for surviving patients. LF was significantly associated with OS (hazard ratio [HR] 1.70 [95% confidence interval {CI} 1.37–2.10]), PCSS (3.10 [95% CI 2.33–4.12]), and DMFS (HR 1.92 [95% CI 1.54–2.39]), p < 0.001 for all). Patients who had not transitioned to the LF state had a significantly lower hazard of transitioning to a PCa-specific death state than those who transitioned to the LF state (HR 0.13 [95% CI 0.04–0.41], p < 0.001). Additionally, patients who transitioned to the LF state had a greater hazard of DM or death (HR 2.46 [95% CI 1.22–4.93], p = 0.01) than those who did not. LF is an independent prognosticator of OS, PCSS, and DMFS in high-grade localized PCa and a subset of DM events that are anteceded by LF events. LF events warrant consideration for intervention, potentially suggesting a rationale for upfront treatment intensification. However, whether these findings apply to all men or just those without significant comorbidity remains to be determined. Men who experience a local recurrence of high-grade prostate cancer after receiving upfront radiation therapy are at significantly increased risks of developing metastases and dying of prostate cancer. Using individual patient-level data from six randomized trials, we have found that local failure events after definitive radiotherapy for high-grade prostate cancer are independent, significant predictors of distant metastasis–free survival, prostate cancer–specific survival, and overall survival. Using multistate modeling, we identify that most distant metastatic events occur from an apparent disease-free state, but an increasing proportion occurs over time subsequent to local failure events. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
31. Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection.
- Author
-
Johnson, David C., Yang, Jason J., Kwan, Lorna, Barsa, Danielle E., Mirak, Sohrab A., Pooli, Aydin, Sadun, Taylor, Jayadevan, Rajiv, Zhou, Steve, Priester, Alan M., Natarajan, Shyam, Bajgiran, Amirhossein M., Shakeri, Sepideh, Sisk, Anthony, Felker, Ely R., Raman, Steven S., Marks, Leonard S., and Reiter, Robert E.
- Subjects
- *
PATIENT selection , *PROSTATE cancer , *PROSTATE biopsy , *MAGNETIC resonance imaging , *BIOPSY , *PROSTATE-specific antigen - Abstract
Background: Hemiablation is a less morbid treatment alternative for appropriately selected patients with unilateral prostate cancer (PCa). However, to the authors' knowledge, traditional diagnostic techniques inadequately identify appropriate candidates. In the current study, the authors quantified the accuracy for identifying hemiablation candidates using contemporary diagnostic techniques, including multiparametric magnetic resonance imaging (mpMRI) and MRI‐fusion with complete systematic template biopsy. Methods: A retrospective analysis of patients undergoing MRI and MRI‐fusion prostate biopsy, including full systematic template biopsy, prior to radical prostatectomy in a single tertiary academic institution between June 2010 and February 2018 was performed. Hemiablation candidates had unilateral intermediate‐risk PCa (Gleason score [GS] of 3+4 or 4+3, clinical T classification ≤T2, and prostate‐specific antigen level <20 ng/dL) on MRI‐fusion biopsy and 2) no contralateral highly or very highly suspicious Prostate Imaging Reporting and Data System version 2 (PI‐RADSv2) MRI lesions. Hemiablation candidates were inappropriately selected if pathologists identified contralateral GS ≥3+4 or high‐risk ipsilateral PCa on prostatectomy. The authors tested a range of hemiablation inclusion criteria and performed multivariable analysis of preoperative predictors of undetected contralateral disease. Results: Of 665 patients, 92 met primary hemiablation criteria. Of these 92 patients, 44 (48%) were incorrectly identified due to ipsilateral GS ≥3+4 tumors crossing the midline (21 patients), undetected distinct contralateral GS ≥3+4 tumors (20 patients), and/or ipsilateral high‐risk PCa (3 patients) on prostatectomy. The rate of undetected contralateral disease ranged from 41% to 48% depending on inclusion criteria. On multivariable analysis, men with anterior index tumors were found to be 2.4 times more likely to harbor undetected contralateral GS ≥3+4 PCa compared with men with posterior lesions (P < .05). Conclusions: Clinicians and patients must weigh the risk of inadequate oncologic treatment against the functional benefits of hemiablation. Further investigation into methods for improving patient selection for hemiablation is necessary. Even with contemporary diagnostic techniques, including magnetic resonance imaging (MRI), MRI‐fusion biopsy, and systematic template biopsy, appropriately identifying unilateral prostate cancer remains difficult. Nearly one‐half of hemiablation candidates based on preoperative radiographic, clinical, and pathologic factors harbored pathology, making them inappropriate for hemiablation in their radical prostatectomy specimen. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
32. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
- Author
-
Calais, Jeremie, Ceci, Francesco, Eiber, Matthias, Hope, Thomas A, Hofman, Michael S, Rischpler, Christoph, Bach-Gansmo, Tore, Nanni, Cristina, Savir-Baruch, Bital, Elashoff, David, Grogan, Tristan, Dahlbom, Magnus, Slavik, Roger, Gartmann, Jeannine, Nguyen, Kathleen, Lok, Vincent, Jadvar, Hossein, Kishan, Amar U, Rettig, Matthew B, and Reiter, Robert E
- Subjects
- *
STATISTICAL power analysis , *KARNOFSKY Performance Status , *PROSTATE-specific antigen , *CANCER relapse , *PELVIS , *EVALUATION research , *RESEARCH funding , *ETHYLENEDIAMINETETRAACETIC acid , *HYDROCARBONS , *OLIGOPEPTIDES , *PROSTATE tumors , *CARBOXYLIC acids , *LONGITUDINAL method , *PROSTATECTOMY , *PROSTATE-specific membrane antigen , *RESEARCH methodology , *RESEARCH , *COMPARATIVE studies , *CONTRAST media , *DRUG dosage , *DRUG administration - Abstract
Background: National Comprehensive Cancer Network guidelines consider 18F-fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical prostatectomy, whereas European Association of Urology guidelines recommend prostate-specific membrane antigen (PSMA) PET-CT. To the best of our knowledge, no prospective head-to-head comparison between these tests has been done so far. The aim of this study was to compare prospectively paired 18F-fluciclovine and PSMA PET-CT scans for localising biochemical recurrence of prostate cancer after radical prostatectomy in patients with low prostate-specific antigen (PSA) concentrations (<2·0 ng/mL).Methods: This was a prospective, single-centre, open-label, single-arm comparative study done at University of California Los Angeles (Los Angeles, CA, USA). Patients older than 18 years of age with prostate cancer biochemical recurrence after radical prostatectomy and PSA levels ranging from 0·2 to 2·0 ng/mL without any prior salvage therapy and with a Karnofsky performance status of at least 50 were eligible. Patients underwent 18F-fluciclovine (reference test) and PSMA (index test) PET-CT scans within 15 days. Detection rate of biochemical recurrence at the patient level and by anatomical region was the primary endpoint. A statistical power analysis demonstrated that a sample size of 50 patients was needed to show a 22% difference in detection rates in favour of PSMA (test for superiority). Each PET scan was interpreted by three independent masked readers and a consensus majority interpretation was generated (two vs one) to determine positive findings. This study is registered with ClinicalTrials.gov, number NCT02940262, and is complete.Findings: Between Feb 26, 2018, and Sept 20, 2018, 143 patients were screened for eligibility, of whom 50 patients were enrolled into the study. Median follow-up was 8 months (IQR 7-9). The primary endpoint was met; detection rates were significantly lower with 18F-fluciclovine PET-CT (13 [26%; 95% CI 15-40] of 50) than with PSMA PET-CT (28 [56%; 41-70] of 50), with an odds ratio (OR) of 4·8 (95% CI 1·6-19·2; p=0·0026) at the patient level; in the subanalysis of the pelvic nodes region (four [8%; 2-19] with 18F-fluciclovine vs 15 [30%; 18-45] with PSMA PET-CT; OR 12·0 [1·8-513·0], p=0·0034); and in the subanalysis of any extrapelvic lesions (none [0%; 0-6] vs eight [16%; 7-29]; OR non-estimable [95% CI non-estimable], p=0·0078).Interpretation: With higher detection rates, PSMA should be the PET tracer of choice when PET-CT imaging is considered for subsequent treatment management decisions in patients with prostate cancer and biochemical recurrence after radical prostatectomy and low PSA concentrations (≤2·0 ng/mL). Further research is needed to investigate whether higher detection rates translate into improved oncological outcomes.Funding: None. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
33. Cancer core length from targeted biopsy: an index of prostate cancer volume and pathological stage.
- Author
-
Simopoulos, Demetrios N., Sisk, Anthony E., Priester, Alan, Felker, Ely R., Kwan, Lorna, Delfin, Merdie K., Reiter, Robert E., and Marks, Leonard S.
- Subjects
- *
PROSTATE cancer , *PROSTATE biopsy , *MAGNETIC resonance imaging , *GLEASON grading system , *CANCER , *PROSTATE cancer patients - Abstract
Objective: To study the relationship of maximum cancer core length (MCCL), on targeted biopsy (TB) of magnetic resonance imaging (MRI)‐visible index lesions, to volume of that tumour found at radical prostatectomy (RP). Patients and Methods: In all, 205 men undergoing fusion biopsy and RP were divided into two groups: 136 in whom the MCCL came from an index MRI‐visible lesion (TB) and 69 in whom MCCL came from a non‐targeted lesion (non‐targeted biopsy [NTB]). MRI was 3‐T multi‐parametric and biopsy was via MRI‐ultrasonography fusion. Results: In the TB group, MCCL correlated with volume of clinically significant index tumours (ρ = 0.44–0.60, P < 0.01). The correlation was similar for first and repeat biopsy and for transition and peripheral zone lesions (ρ = 0.42–0.49, P < 0.01). No correlations were found in the NTB group. TB MCCL (6–10 and >10 mm) and MRI lesion diameter (>20 mm) were independently associated with tumour volume. TB MCCLs >10 mm and Gleason scores >7 were each associated with pathological T3 disease (odds ratios 5.73 and 5.04, respectively), but MRI lesion diameter lesion was not. Conclusions: MCCL on a TB from an MRI‐visible lesion is an independent predictor of both cancer volume and pathological stage. This relationship does not exist for MCCL from a NTB core. Quantifying CCL on MRI‐TBs may have a value, not previously described, to risk‐stratify patients with prostate cancer before treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.
- Author
-
Houlahan, Kathleen E., Salmasi, Amirali, Sadun, Taylor Y., Pooli, Aydin, Felker, Ely R., Livingstone, Julie, Huang, Vincent, Raman, Steven S., Ahuja, Preeti, Sisk, Anthony E., Boutros, Paul C., and Reiter, Robert E.
- Subjects
- *
MAGNETIC resonance imaging , *TUMOR grading , *PROSTATE cancer , *PROSTATE tumors , *VISIBILITY , *DIAGNOSIS - Abstract
Multiparametric magnetic resonance imaging (mpMRI) has transformed the management of localized prostate cancer by improving identification of clinically significant disease at diagnosis. Approximately 20% of primary prostate tumors are invisible to mpMRI, and we hypothesize that this invisibility reflects fundamental molecular properties of the tumor. We therefore profiled the genomes and transcriptomes of 40 International Society of Urological Pathology grade 2 tumors: 20 mpMRI-invisible (Prostate Imaging-Reporting and Data System [PI-RADS] v2 <3) and 20 mpMRI-visible (PI-RADS v2 5) tumors. mpMRI-visible tumors were enriched in hallmarks of nimbosus, an aggressive pathological, molecular, and microenvironmental phenomenon in prostate cancer. These hallmarks included genomes with increased mutation density, a higher prevalence of intraductal carcinoma/cribriform architecture pathology, and altered abundance of 102 transcripts, including overexpression of noncoding RNAs such as SCHLAP1. Multiple small nucleolar RNAs (snoRNAs) were identified, and a snoRNA signature synergized with nimbosus hallmarks to discriminate visible from invisible tumors. These data suggest a confluence of aggressive molecular and microenvironmental phenomena underlie mpMRI visibility of localized prostate cancer. We examined the correlation between tumor biology and magnetic resonance imaging (MRI) visibility in a group of patients with low- intermediate-risk prostate cancer. We observed that MRI findings are associated with biological features of aggressive prostate cancer. Genome-wide copy number alteration and transcriptomic profiling of tumors invisible and visible on multiparametric magnetic resonance imaging (mpMRI) identified a confluence of aggressive transcriptomic, genomic, and pathological hallmarks correlated with mpMRI visibility. This work provides a molecular basis for the observation that mpMRI-visible tumors are clinically more aggressive. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
- Author
-
Johnson, David C., Raman, Steven S., Mirak, Sohrab A., Kwan, Lorna, Bajgiran, Amirhossein M., Hsu, William, Maehara, Cleo K., Ahuja, Preeti, Faiena, Izak, Pooli, Aydin, Salmasi, Amirali, Sisk, Anthony, Felker, Ely R., Lu, David S.K., and Reiter, Robert E.
- Subjects
- *
PROSTATE cancer , *MAGNETIC resonance imaging , *PROSTATE tumors , *STATISTICAL measurement , *PROSTATE-specific antigen , *GLEASON grading system - Abstract
Abstract Background Multiparametric magnetic resonance imaging (mpMRI) undoubtedly affects the diagnosis and treatment of localized prostate cancer (CaP). However, clinicians need a better understanding of its accuracy and limitations in detecting individual CaP foci to optimize management. Objective To determine the per-lesion detection rate for CaP foci by mpMRI and identify predictors of tumor detection. Design, setting, and participants We carried out a retrospective analysis of a prospectively managed database correlating lesion-specific results from mpMRI co-registered with whole-mount pathology (WMP) prostatectomy specimens from June 2010 to February 2018. Participants include 588 consecutive patients with biopsy-proven CaP undergoing 3-T mpMRI before radical prostatectomy at a single tertiary institution. Outcome measurements and statistical analysis We measured mpMRI sensitivity in detecting individual CaP and clinically significant (any Gleason score ≥7) CaP foci and predictors of tumor detection using multivariate analysis. Results and limitations The final analysis included 1213 pathologically confirmed tumor foci in 588 patients with primarily intermediate- (75%) or high-risk (12%) CaP. mpMRI detected 45% of all lesions (95% confidence interval [CI] 42–47%), including 65% of clinically significant lesions (95% CI 61–69%) and nearly 80% of high-grade tumors. Some 74% and 31% of missed solitary and multifocal tumors, respectively, were clinically significant. The majority of missed lesions were small (61.1% ≤1 cm); 28.3% were between 1 and 2 cm, and 10.4% were >2 cm. mpMRI missed at least one clinically significant focus in 34% of patients overall, and in 45% of men with multifocal lesions. On multivariate analysis, smaller, low-grade, multifocal, nonindex tumors with lower prostate-specific antigen density were more likely to be missed. Limitations include selection bias in a prostatectomy cohort, lack of specificity data, an imperfect co-registration process, and uncertain clinical significance for undetected lesions. Conclusions mpMRI detects less than half of all and less than two-thirds of clinically significant CaP foci. The moderate per-lesion sensitivity and significant proportion of men with undetected tumor foci demonstrate the current limitations of mpMRI. Patient summary Magnetic resonance imaging of the prostate before surgical removal for prostate cancer finds less than half of all individual prostate cancer tumors. Large, solitary, aggressive tumors are more likely to be visualized on imaging. Take Home Message In this retrospective review of robotic radical prostatectomy specimens for prostate cancer processed using whole-mount pathology, 3-T multiparametric magnetic resonance imaging detected 45% of all individual prostate cancers and 65% of clinically significant tumors. Smaller, low-risk, nonindex, and multifocal tumors were more likely to be missed. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
- Author
-
Parikh, Neil R., Huiza, Claudia, Patel, Jill S., Tsai, Sonny, Kalpage, Nathisha, Thein, May, Pitcher, Sage, Lee, Steve P., Inouye, Warren S., Jordan, Mark L., Sanati, Homayoon, Jafari, Lida, Bennett, Carol J., Gin, Greg E., Kishan, Amar U., Reiter, Robert E., Lewis, Michael, Sadeghi, Ahmad, Aronson, William J., and Garraway, Isla P.
- Subjects
- *
PROSTATE cancer , *CASTRATION-resistant prostate cancer , *ABIRATERONE acetate , *STEREOTACTIC radiotherapy , *HORMONE therapy , *VETERANS - Abstract
Background: The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) patients is evolving. PET/CT now offers improved sensitivity and accuracy in staging. Recent randomized trial data supports escalated hormone therapy, local primary tumor therapy, and metastasis-directed therapy. The impact of combining such therapies into a multimodal approach is unknown. This Phase II single-arm clinical trial sponsored and funded by Veterans Affairs combines local, metastasis-directed, and systemic therapies to durably render patients free of detectable disease off active therapy.Methods: Patients with newly-diagnosed M1a/b prostate cancer (PSMA PET/CT staging is permitted) and 1-5 radiographically visible metastases (excluding pelvic lymph nodes) are undergoing local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present. The primary endpoint is the percent of patients achieving a serum PSA of < 0.05 ng/mL six months after recovery of serum testosterone ≥150 ng/dL. Secondary endpoints include time to biochemical progression, time to radiographic progression, time to initiation of alternative antineoplastic therapy, prostate cancer specific survival, health related quality-of-life, safety and tolerability.Discussion: To our knowledge, this is the first trial that tests a comprehensive systemic and tumor directed therapeutic strategy for patients with newly diagnosed oligometastatic prostate cancer. This trial, and others like it, represent the critical first step towards curative intent therapy for a patient population where palliation has been the norm.Trial Registration: Clinicaltrials.gov identifier: NCT03298087 (registration date: September 29, 2017). [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
37. 3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard.
- Author
-
Asvadi, Nazanin Hajarol, Afshari Mirak, Sohrab, Mohammadian Bajgiran, Amirhossein, Khoshnoodi, Pooria, Raman, Steven S., Wibulpolprasert, Pornphan, Margolis, Daniel, Sisk, Anthony, and Reiter, Robert E.
- Subjects
- *
MAGNETIC resonance imaging , *TISSUE wounds , *PROSTATE cancer , *RADIOLOGY , *ANTIGENS - Abstract
Purpose: To evaluate 3T mpMRI characteristics of transition zone and peripheral zone index prostate cancer lesions stratified by Gleason Score and PI-RADSv2 with whole mount histopathology correlation.Methods: An institution review board-approved, HIPAA-compliant single-arm observational study of 425 consecutive men with 3T mpMRI prior to radical prostatectomy from December 2009 to October 2016 was performed. A genitourinary radiologist and a genitourinary pathologist matched all lesions detected on whole mount histopathology with lesions concordant for size and location on 3T mpMRI. Differences in clinical, MRI parameters, and histopathology between transition zone and peripheral zone were determined and analyzed with χ2 and Mann-Whitney U test. AUC was measured.Results: 3T mpMRI detected 248/323 (76.7%) index lesions in peripheral zone and 75/323 (23.2%) in transition zone. Transition zone prostate cancer had higher median prostate-specific antigen (p = 0.001), larger tumor on 3T mpMRI (p = 0.001), lower proportions of PI-RADSv2 category 4 and 5 (p < 0.001), and lower pathological stage (p = 0.055) compared to peripheral zone prostate cancer. No significant differences were detected in prostate-specific antigen density, preoperative biopsy, and pathology Gleason Scores. After adjusting for significant variables from univariate analysis including prostate volume, tumor volume, prostate-specific antigen, PI-RADSv2 category, AUC for predicting clinically significant tumor in transition zone and peripheral zone were 0.80 and 0.72, respectively (p = 0.36).Conclusions: The diagnostic performance of PI-RADSv2 for clinically significant transition and peripheral zone prostate cancer was similar. However, there was a lower portion of PI-RADSv2 4 and 5 lesions in transition zone compared to peripheral zone. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
38. Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate.
- Author
-
Nagarajan, Mahesh B., Raman, Steven S., Lo, Pechin, Lin, Wei-Chan, Khoshnoodi, Pooria, Sayre, James W., Ramakrishna, Bharath, Ahuja, Preeti, Huang, Jiaoti, Margolis, Daniel J. A., Lu, David S. K., Reiter, Robert E., Goldin, Jonathan G., Brown, Matthew S., and Enzmann, Dieter R.
- Subjects
- *
BIOPSY , *PROSTATE tumors , *PROSTATE cancer , *PROSTATECTOMY , *MAGNETIC resonance imaging , *MEDICAL radiology - Abstract
Purpose: We present a method for generating a T2 MR-based probabilistic model of tumor occurrence in the prostate to guide the selection of anatomical sites for targeted biopsies and serve as a diagnostic tool to aid radiological evaluation of prostate cancer.Materials and methods: In our study, the prostate and any radiological findings within were segmented retrospectively on 3D T2-weighted MR images of 266 subjects who underwent radical prostatectomy. Subsequent histopathological analysis determined both the ground truth and the Gleason grade of the tumors. A randomly chosen subset of 19 subjects was used to generate a multi-subject-derived prostate template. Subsequently, a cascading registration algorithm involving both affine and non-rigid B-spline transforms was used to register the prostate of every subject to the template. Corresponding transformation of radiological findings yielded a population-based probabilistic model of tumor occurrence. The quality of our probabilistic model building approach was statistically evaluated by measuring the proportion of correct placements of tumors in the prostate template, i.e., the number of tumors that maintained their anatomical location within the prostate after their transformation into the prostate template space.Results: Probabilistic model built with tumors deemed clinically significant demonstrated a heterogeneous distribution of tumors, with higher likelihood of tumor occurrence at the mid-gland anterior transition zone and the base-to-mid-gland posterior peripheral zones. Of 250 MR lesions analyzed, 248 maintained their original anatomical location with respect to the prostate zones after transformation to the prostate.Conclusion: We present a robust method for generating a probabilistic model of tumor occurrence in the prostate that could aid clinical decision making, such as selection of anatomical sites for MR-guided prostate biopsies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
39. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
- Author
-
Wyatt, Alexander W., Annala, Matti, Aggarwal, Rahul, Beja, Kevin, Felix Feng, Youngren, Jack, Foye, Adam, Lloyd, Paul, Nykter, Matti, Beer, Tomasz M., Alumkal, Joshi J., Thomas, George V., Reiter, Robert E., Rettig, Matthew B., Evans, Christopher P., Gao, Allen C., Chi, Kim N., Small, Eric J., and Gleave, Martin E.
- Abstract
Background: Real-time knowledge of the somatic genome can influence management of patients with metastatic castrationresistant prostate cancer (mCRPC). While routine metastatic tissue biopsy is challenging in mCRPC, plasma circulating tumor DNA (ctDNA) has emerged as a minimally invasive tool to sample the tumor genome. However, no systematic comparisons of matched "liquid" and "solid" biopsies have been performed that would enable ctDNA profiling to replace the need for direct tissue sampling. Methods: We performed targeted sequencing across 72 clinically relevant genes in 45 plasma cell-free DNA (cfDNA) samples collected at time of metastatic tissue biopsy. We compared ctDNA alterations with exome sequencing data generated from matched tissue and quantified the concordance of mutations and copy number alterations using the Fisher exact test and Pearson correlations. Results: Seventy-five point six percent of cfDNA samples had a ctDNA proportion greater than 2% of total cfDNA. In these patients, all somatic mutations identified in matched metastatic tissue biopsies were concurrently present in ctDNA. Furthermore, the hierarchy of variant allele fractions for shared mutations was remarkably similar between ctDNA and tissue. Copy number profiles between matched liquid and solid biopsy were highly correlated, and individual copy number calls in clinically actionable genes were 88.9% concordant. Detected alterations included AR amplifications in 22 (64.7%) samples, SPOP mutations in three (8.8%) samples, and inactivating alterations in tumor suppressors TP53, PTEN, RB1, APC, CDKN1B, BRCA2, and PIK3R1. In several patients, ctDNA sequencing revealed robust changes not present in paired solid biopsy, including clinically relevant alterations in the AR, WNT, and PI3K pathways. Conclusions: Our study shows that, in the majority of patients, a ctDNA assay is sufficient to identify all driver DNA alterations present in matched metastatic tissue and supports development of DNA biomarkers to guide mCRPC patient management based on ctDNA alone. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
40. Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.
- Author
-
Hegde, John V., Veruttipong, Darlene, Said, Jonathan W., Reiter, Robert E., Steinberg, Michael L., King, Christopher R., and Kishan, Amar U.
- Subjects
- *
PROSTATE cancer risk factors , *PROSTATE cancer treatment , *PROGRESSION-free survival , *RETROSPECTIVE studies ,PROSTATECTOMY complications - Abstract
Objective: To evaluate whether preoperative urinary prostate cancer antigen 3 (PCA3) scores predict for adverse pathologic features (APFs) or progression-free survival (PFS) in men with intermediate- or high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).Materials and Methods: One hundred nine men with intermediate- (n = 52) or high-risk (n = 57) PCa who underwent RP were retrospectively identified. Logistic regression analysis was performed to evaluate the association of PCA3 score with various APFs (eg, extracapsular extension, seminal vesicle invasion, etc.). Among 78 men with ≥1 year of follow-up, the association between PCA3 score and PFS was assessed using Cox regression analysis.Results: At RP, 52% of patients had at least 1 APF, and with median follow-up of 2.3 years, overall 3-year PFS was 70%. PCA3 was not a significant predictor of any APF on multivariate analysis (MVA), whereas canonical predictors (eg, biopsy Gleason score and initial prostate-specific antigen) remained predictive of various APFs. No significant predictors for PFS were found on MVA, although certain canonical predictors (eg, National Comprehensive Cancer Network risk group) were significant predictors of PFS on univariate analysis (UVA). PCA3 score was not a significant predictor of PFS on either UVA or MVA.Conclusion: Unlike in lower risk cohorts, increasing PCA3 score was not associated with any APF in this higher risk cohort, despite enrichment for APFs, nor was it associated with PFS. Notably, multiple known preoperative predictors for APFs were significant on MVA, and multiple predictors were associated with PFS on UVA. Therefore, PCA3 may not be a useful adjunct predictive marker in men with intermediate- or high-risk PCa. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
41. Use of the Electronic Medical Record to Facilitate Intervention for Patients With Rising Prostate-Specific Antigen Values After Radical Prostatectomy: A Feasibility Study.
- Author
-
Kishan, Amar U., Cheng, Eric M., Schmidt, Eric, Saigal, Christopher, Reiter, Robert E., Kupelian, Patrick A., Steinberg, Michael L., and King, Christopher R.
- Subjects
- *
ELECTRONIC health records , *PROSTATE-specific antigen , *PROSTATECTOMY , *PROSTATE cancer treatment , *FEASIBILITY studies - Abstract
Purpose Salvage radiotherapy (SRT) is the standard of care offered when postprostatectomy prostatespecific antigen (PSA) levels are ≥ 0.2 ng/mL. However, emerging evidence suggests that early SRT (ie, SRT delivered at PSA values < 0.2 ng/mL, but generally ≥ 0.05 ng/mL) improves oncologic outcomes. We evaluated the feasibility of improving referral rates for discussion of early SRT by using a dynamic registry that identifies through the electronic medical record patients with rising postprostatectomy PSA levels. Methods We developed an iteratively updated registry that identifies patients who fall within two postoperative PSA strata: ≥ 0.05 to < 0.1 ng/mL and ≥ 0.1 to < 0.2 ng/mL. We compared referral rates to radiation oncology during a 3-year period before use of this registry with those during a 1-year period after promotion of the registry in multidisciplinary tumor board settings. Results Before promotion of the registry, referral rates for patients with PSA values ≥ 0.05 to < 0.1 ng/mL and ≥ 0.1 to < 0.2 ng/mL were 35% and 65%, respectively. After promotion of the registry, referral rates within each stratum increased significantly to 82% and 94%, respectively (P < .05 for both by Fisher's exact test). The overall rate of referral for patients with PSA values ≥ 0.05 to < 0.2 ng/mL rose from 48% to 90% (P < .001). Conclusion The creation of a registry of patients with rising postprostatectomy PSA values can facilitate increased referral rates for early SRT without burdening providers with a clinical support tool embedded within the EMR itself. This is true even in the case of already high baseline rates of referral for early SRT. The changes reported herein most likely reflect a Hawthorne effect wherein the ability to track referrals rather than a direct function of the registry influenced practice patterns. Nonetheless, the registry provided an integral framework to allow for tracking. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
42. Clinical Outcomes for Patients with Gleason Score 9–10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
- Author
-
Kishan, Amar U., Shaikh, Talha, Wang, Pin-Chieh, Reiter, Robert E., Said, Jonathan, Raghavan, Govind, Nickols, Nicholas G., Aronson, William J., Sadeghi, Ahmad, Kamrava, Mitchell, Demanes, David Jeffrey, Steinberg, Michael L., Horwitz, Eric M., Kupelian, Patrick A., and King, Christopher R.
- Subjects
- *
PROSTATE cancer treatment , *ADENOCARCINOMA , *CANCER radiotherapy , *NATURAL history , *GLEASON grading system - Abstract
Background The long natural history of prostate cancer (CaP) limits comparisons of efficacy between radical prostatectomy (RP) and external beam radiotherapy (EBRT), since patients treated years ago received treatments considered suboptimal by modern standards (particularly with regards to androgen deprivation therapy [ADT] and radiotherapy dose-escalation]. Gleason score (GS) 9–10 CaP is particularly aggressive, and clinically-relevant endpoints occur early, facilitating meaningful comparisons. Objective To compare outcomes of patients with GS 9–10 CaP following EBRT, extremely-dose escalated radiotherapy (as exemplified by EBRT + brachytherapy [EBRT + BT]), and RP. Design, setting, participants Retrospective analysis of 487 patients with biopsy GS 9–10 CaP treated between 2000 and 2013 (230 with EBRT, 87 with EBRT + BT, and 170 with RP). Most radiotherapy patients received ADT and dose-escalated radiotherapy. Outcome measurements and statistical analysis Kaplan-Meier analysis and multivariate Cox regression estimated and compared 5-yr and 10-yr rates of distant metastasis-free survival, cancer-specific survival (CSS), and overall survival (OS). Results and limitations The median follow-up was 4.6 yr. Local salvage and systemic salvage were performed more frequently in RP patients (49.0% and 30.1%) when compared with either EBRT patients (0.9% and 19.7%) or EBRT + BT patients (1.2% and 16.1%, p < 0.0001). Five-yr and 10-yr distant metastasis-free survival rates were significantly higher with EBRT + BT (94.6% and 89.8%) than with EBRT (78.7% and 66.7%, p = 0.0005) or RP (79.1% and 61.5%, p < 0.0001). The 5-yr and 10-yr CSS and OS rates were similar across all three cohorts. Conclusions Radiotherapy and RP provide equivalent CSS and OS. Extremely dose-escalated radiotherapy with ADT in particular offers improved systemic control when compared with either EBRT or RP. These data suggest that extremely dose-escalated radiotherapy with ADT might be the optimal upfront treatment for patients with biopsy GS 9–10 CaP. Patient summary While some prostate cancers are slow-growing requiring many years, sometimes decades, of follow-up in order to compare between radiation and surgery, high-risk and very aggressive cancers follow a much shorter time course allowing such comparisons to be made and updated as treatments, especially radiation, rapidly evolve. We showed that radiation-based treatments and surgery, with contemporary standards, offer equivalent survival for patients with very aggressive cancers (defined as Gleason score 9–10). Extremely-dose escalated radiotherapy with short-course androgen deprivation therapy offered the least risk of developing metastases, and equivalent long term survival. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
43. Use of the Electronic Medical Record to Facilitate Intervention for Patients With Rising Prostate-Specific Antigen Values After Radical Prostatectomy: A Feasibility Study.
- Author
-
Kishan, Amar U., Cheng, Eric M., Schmidt, Eric, Saigal, Christopher, Reiter, Robert E., Kupelian, Patrick A., Steinberg, Michael L., and King, Christopher R.
- Subjects
- *
PROSTATE-specific antigen , *ELECTRONIC health records , *FISHER exact test , *PROSTATECTOMY , *FEASIBILITY studies , *HAWTHORNE effect - Abstract
Purpose: Salvage radiotherapy (SRT) is the standard of care offered when postprostatectomy prostate-specific antigen (PSA) levels are ≥ 0.2 ng/mL. However, emerging evidence suggests that early SRT (ie, SRT delivered at PSA values < 0.2 ng/mL, but generally ≥ 0.05 ng/mL) improves oncologic outcomes. We evaluated the feasibility of improving referral rates for discussion of early SRT by using a dynamic registry that identifies through the electronic medical record patients with rising postprostatectomy PSA levels. Methods: We developed an iteratively updated registry that identifies patients who fall within two postoperative PSA strata: ≥ 0.05 to < 0.1 ng/mL and ≥ 0.1 to < 0.2 ng/mL. We compared referral rates to radiation oncology during a 3-year period before use of this registry with those during a 1-year period after promotion of the registry in multidisciplinary tumor board settings. Results: Before promotion of the registry, referral rates for patients with PSA values ≥ 0.05 to < 0.1 ng/mL and ≥ 0.1 to < 0.2 ng/mL were 35% and 65%, respectively. After promotion of the registry, referral rates within each stratum increased significantly to 82% and 94%, respectively (P <.05 for both by Fisher's exact test). The overall rate of referral for patients with PSA values ≥ 0.05 to < 0.2 ng/mL rose from 48% to 90% (P <.001). Conclusion: The creation of a registry of patients with rising postprostatectomy PSA values can facilitate increased referral rates for early SRT without burdening providers with a clinical support tool embedded within the EMR itself. This is true even in the case of already high baseline rates of referral for early SRT. The changes reported herein most likely reflect a Hawthorne effect wherein the ability to track referrals rather than a direct function of the registry influenced practice patterns. Nonetheless, the registry provided an integral framework to allow for tracking. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
44. Use of the Electronic Medical Record to Facilitate Intervention for Patients With Rising Prostate-Specific Antigen Values After Radical Prostatectomy: A Feasibility Study.
- Author
-
Kishan, Amar U., Cheng, Eric M., Schmidt, Eric, Saigal, Christopher, Reiter, Robert E., Kupelian, Patrick A., Steinberg, Michael L., and King, Christopher R.
- Subjects
- *
SALVAGE therapy , *RADIOTHERAPY , *MANAGEMENT of medical records , *PROSTATECTOMY , *PROSTATE cancer patients , *PROSTATE cancer treatment , *HAWTHORNE effect - Abstract
Purpose Salvage radiotherapy (SRT) is the standard of care offered when postprostatectomy prostatespecific antigen (PSA) levels are ≥ 0.2 ng/mL. However, emerging evidence suggests that early SRT (ie, SRT delivered at PSA values < 0.2 ng/mL, but generally ≥ 0.05 ng/mL) improves oncologic outcomes. We evaluated the feasibility of improving referral rates for discussion of early SRT by using a dynamic registry that identifies through the electronic medical record patients with rising postprostatectomy PSA levels. Methods We developed an iteratively updated registry that identifies patients who fall within two postoperative PSA strata: ≥ 0.05 to < 0.1 ng/mL and ≥ 0.1 to < 0.2 ng/mL. We compared referral rates to radiation oncology during a 3-year period before use of this registry with those during a 1-year period after promotion of the registry in multidisciplinary tumor board settings. Results Before promotion of the registry, referral rates for patients with PSA values ≥ 0.05 to < 0.1 ng/mL and ≥ 0.1 to < 0.2 ng/mL were 35% and 65%, respectively. After promotion of the registry, referral rates within each stratum increased significantly to 82% and 94%, respectively (P < .05 for both by Fisher's exact test). The overall rate of referral for patients with PSA values ≥ 0.05 to < 0.2 ng/mL rose from 48% to 90% (P < .001). Conclusion The creation of a registry of patients with rising postprostatectomy PSA values can facilitate increased referral rates for early SRT without burdening providers with a clinical support tool embedded within the EMR itself. This is true even in the case of already high baseline rates of referral for early SRT. The changes reported herein most likely reflect a Hawthorne effect wherein the ability to track referrals rather than a direct function of the registry influenced practice patterns. Nonetheless, the registry provided an integral framework to allow for tracking. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
45. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
- Author
-
Stoyanova, Tanya, Riedinger, Mireille, Shu Lin, Faltermeier, Claire M., Smith, Bryan A., Zhang, Kelvin X., Going, Catherine C., Goldstein, Andrew S., Lee, John K., Drake, Justin M., Rice, Meghan A., En-Chi Hsu, Nowroozizadeh, Behdokht, Castor, Brandon, Orellana, Sandra Y., Blu, Steven M., Donghui Cheng, Pienta, Kenneth J., Reiter, Robert E., and Pitteri, Sharon J.
- Subjects
- *
PROSTATE cancer , *CANCER , *PROSTATE , *ADENOCARCINOMA , *TUMORS - Abstract
Metastatic castration-resistant prostate cancer (CRPC) is the primary cause of prostate cancer-specific mortality. Defining new mechanisms that can predict recurrence and drive lethal CRPC is critical. Here, we demonstrate that localized high-risk prostate cancer and metastatic CRPC, but not benign prostate tissues or low/intermediate-risk prostate cancer, express high levels of nuclear Notch homolog 1, translocation-associated (Notch1) receptor intracellular domain. Chronic activation of Notch1 synergizes with multiple oncogenic pathways altered in early disease to promote the development of prostate adenocarcinoma. These tumors display features of epithelial-to-mesenchymal transition, a cellular state associated with increased tumor aggressiveness. Consistent with its activation in clinical CRPC, tumors driven by Notch1 intracellular domain in combination with multiple pathways altered in prostate cancer are metastatic and resistant to androgen deprivation. Our study provides functional evidence that the Notch1 signaling axis synergizes with alternative pathways in promoting metastatic CRPC and may represent a new therapeutic target for advanced prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
46. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
- Author
-
Filson, Christopher P., Natarajan, Shyam, Margolis, Daniel J.A., Huang, Jiaoti, Lieu, Patricia, Dorey, Frederick J., Reiter, Robert E., and Marks, Leonard S.
- Subjects
- *
PROSTATE cancer , *MAGNETIC resonance , *ANTIGENS , *MAGNETIC resonance imaging , *CLINICAL trials , *BIOPSY , *COMPARATIVE studies , *DIAGNOSTIC imaging , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *NEEDLE biopsy , *PROSTATE tumors , *RESEARCH , *RESEARCH funding , *ULTRASONIC imaging , *PROSTATE-specific antigen , *EVALUATION research , *PREDICTIVE tests , *ODDS ratio , *DIAGNOSIS - Abstract
Background: The current study was conducted to evaluate the performance of magnetic resonance (MR)-ultrasound-guided fusion biopsy in diagnosing clinically significant prostate cancer (csCaP).Methods: A total of 1042 men underwent multiparametric MR imaging (mpMRI) and fusion biopsy consecutively in a prospective trial (2009-2014). An expert reader graded mpMRI regions of interest (ROIs) as 1 to 5 using published protocols. The fusion biopsy device was used to obtain targeted cores from ROIs (when present) followed by a fusion image-guided, 12-core systematic biopsy in all men, even if no suspicious ROI was noted. The primary endpoint of the study was the detection of csCaP (ie, Gleason score ≥ 7).Results: Among 825 men with ≥ 1 suspicious ROI of ≥ grade 3, 289 (35%) were found to have csCaP. Powerful predictors of csCaP were ROI grade (grade 5 vs grade 3: odds ratio, 6.5 [P<.01]) and prostate-specific antigen density (each increase of 0.05 ng/mL/cc: odds ratio, 1.4 [P<.01]). Combining systematic and targeted biopsies resulted in the detection of more patients with csCaP (289 patients) than targeting (229 patients) or systematic (199 patients) biopsy alone. Among patients with no suspicious ROI, 35 (16%) were found to have csCaP on systematic biopsy.Conclusions: In this prospective trial, MR-ultrasound fusion biopsy allowed for the detection of csCaP, with a direct relationship noted with ROI grade and prostate-specific antigen density. The combination of targeted and systematic biopsy detected more csCaP than either modality alone; systematic biopsies revealed csCaP in 16% of men with no suspicious MRI target. The advantages of this new biopsy method are apparent, but issues of cost, training, and reliability await resolution before its widespread adoption. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
47. Prostate diffusion imaging with distortion correction.
- Author
-
Rakow-Penner, Rebecca A., White, Nathan S., Margolis, Daniel J.A., Parsons, John Kellogg, Schenker-Ahmed, Natalie, Kuperman, Joshua M., Bartsch, Hauke, Choi, Hyung W., Bradley, William G., Shabaik, Ahmed, Huang, Jiaoti, Liss, Michael A., Marks, Leonard, Kane, Christopher J., Reiter, Robert E., Raman, Steven S., Karow, David S., and Dale, Anders M.
- Subjects
- *
DIFFUSION magnetic resonance imaging , *DIAGNOSIS , *PROSTATE cancer , *PROSTATE biopsy , *STANDARD deviations , *MAGNETIC resonance imaging , *DIAGNOSTIC imaging - Abstract
Purpose Diffusion imaging in the prostate is susceptible to distortion from B0 inhomogeneity. Distortion correction in prostate imaging is not routinely performed, resulting in diffusion images without accurate localization of tumors. We performed and evaluated distortion correction for diffusion imaging in the prostate. Materials and methods 28 patients underwent pre-operative MRI (T2, Gadolinium perfusion, diffusion at b = 800 s/mm 2 ). The restriction spectrum protocol parameters included b-values of 0, 800, 1500, and 4000 s/mm 2 in 30 directions for each nonzero b-value. To correct for distortion, forward and reverse trajectories were collected at b = 0 s/mm 2 . Distortion maps were generated to reflect the offset of the collected data versus the corrected data. Whole-mount histology was available for correlation. Results Across the 27 patients evaluated (excluding one patient due to data collection error), the average root mean square distortion distance of the prostate was 3.1 mm (standard deviation, 2.2 mm; and maximum distortion, 12 mm). Conclusion Improved localization of prostate cancer by MRI will allow better surgical planning, targeted biopsies and image-guided treatment therapies. Distortion distances of up to 12 mm due to standard diffusion imaging may grossly misdirect treatment decisions. Distortion correction for diffusion imaging in the prostate improves tumor localization. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. A fully human scFv phage display library for rapid antibody fragment reformatting.
- Author
-
Li, Keyu, Zettlitz, Kirstin A., Lipianskaya, Julia, Zhou, Yu, Marks, James D., Mallick, Parag, Reiter, Robert E., and Wu, Anna M.
- Subjects
- *
IMMUNOGLOBULINS , *BACTERIOPHAGES , *POLYMERASE chain reaction , *CADHERINS , *MONOVALENT cations , *GEL permeation chromatography - Abstract
Phage display libraries of human single-chain variable fragments (scFvs) are a reliable source of fully human antibodies for scientific and clinical applications. Frequently, scFvs form the basis of larger, bivalent formats to increase valency and avidity. A small and versatile bivalent antibody fragment is the diabody, a cross-paired scFv dimer (~55 kDa). However, generation of diabodies from selected scFvs requires decreasing the length of the interdomain scFv linker, typically by overlap PCR. To simplify this process, we designed two scFv linkers with integrated restriction sites for easy linker length reduction (17-residue to 7-residue or 18-residue to 5-residue, respectively) and generated two fully human scFv phage display libraries. The larger library (9 × 109 functional members) was employed for selection against a model antigen, human N-cadherin, yielding novel scFv clones with low nanomolar monovalent affinities. ScFv clones from both libraries were reformatted into diabodies by restriction enzyme digestion and re-ligation. Size-exclusion chromatography analysis confirmed the proper dimerization of most of the diabodies. In conclusion, these specially designed scFv phage display libraries allow us to rapidly reformat the selected scFvs into diabodies, which can greatly accelerate early stage antibody development when bivalent fragments are needed for candidate screening. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
49. Multifocality and Prostate Cancer Detection by Multiparametric Magnetic Resonance Imaging: Correlation with Whole-mount Histopathology.
- Author
-
Le, Jesse D., Tan, Nelly, Shkolyar, Eugene, Lu, David Y., Kwan, Lorna, Marks, Leonard S., Huang, Jiaoti, Margolis, Daniel J.A., Raman, Steven S., and Reiter, Robert E.
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *MAGNETIC resonance imaging , *STATISTICAL correlation , *HISTOPATHOLOGY , *GENITOURINARY organs , *RADIOLOGISTS , *PROSTATECTOMY - Abstract
Background Multiparametric magnetic resonance imaging (mp-MRI) is increasingly used in prostate cancer (CaP). Understanding the limitations of tumor detection, particularly in multifocal disease, is important in its clinical application. Objective To determine predictors of CaP detection by mp-MRI as confirmed by whole-mount histopathology. Design, setting, and participants A retrospective study was performed of 122 consecutive men who underwent mp-MRI before radical prostatectomy at a single referral academic center. A genitourinary radiologist and pathologist collectively determined concordance. Outcome measurements and statistical analysis The odds of tumor detection were calculated for clinical, MRI, and histopathologic variables using a multivariate logistic regression model. Results and limitations The 122 patients had 283 unique histologically confirmed CaP tumor foci. Gleason score was 6 in 21 (17%), 7 in 88 (72%), and ≥8 in 13 (11%) patients. Of the 122 cases, 44 (36%) had solitary and 78 (64%) had multifocal tumors. Overall mp-MRI sensitivity for tumor detection was 47% (132/283), with increased sensitivity for larger (102/141 [72%] >1.0 cm), higher-grade (96/134 [72%] Gleason ≥7) tumors, and index tumors (98/122 [80%]). Index tumor status, size, and prostate weight were significant predictors of detection in a multivariate analysis, and multifocality did not adversely impact detection of index tumors. A prostatectomy population was necessary by design, which may limit the ability to generalize these results. Conclusions Sensitivity for tumor detection increased with tumor size and grade. Index tumor status and tumor size were the strongest predictors of tumor detection, regardless of tumor focality. Some 80% of index tumors were detected, but nonindex tumor detection, even of high-grade lesions, was poor. These findings have important implications for focal therapy. Patient summary We evaluated the ability of magnetic resonance imaging (MRI) to detect cancer in patients undergoing prostatectomy. We found that tumor size and grade were important predictors of tumor detection, and although cancer is often multifocal, MRI is often able to detect the worst focus of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
50. Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer.
- Author
-
Sonn, Geoffrey A., Filson, Christopher P., Chang, Edward, Natarajan, Shyam, Margolis, Daniel J., Macairan, Malu, Lieu, Patricia, Huang, Jiaoti, Dorey, Frederick J., Reiter, Robert E., and Marks, Leonard S.
- Subjects
- *
PROSTATE cancer , *DIAGNOSIS , *BIOPSY , *MAGNETIC resonance imaging , *ULTRASONIC imaging of cancer , *ONCOLOGY , *HEALTH outcome assessment , *FOLLOW-up studies (Medicine) - Abstract
Objectives Targeted biopsy, using magnetic resonance (MR)-ultrasound (US) fusion, may allow tracking of specific cancer sites in the prostate. We aimed to evaluate the initial use of the technique to follow tumor sites in men on active surveillance of prostate cancer. Methods and materials A total of 53 men with prostate cancer (all T1c category) underwent rebiopsy of 74 positive biopsy sites, which were tracked and targeted using the Artemis MR-US fusion device (Eigen, Grass Valley, CA) from March 2010 through January 2013. The initial biopsy included 12 cores from a standard template (mapped by software) and directed biopsies from regions of interest seen on MR imaging (MRI). In the repeat biopsy, samples were taken from sites containing cancer at the initial biopsy. Outcomes of interest at second MR-US biopsy included (a) presence of any cancer and (b) presence of clinically significant cancer. Results All cancers on initial biopsy had either Gleason score 3+3 = 6 ( n = 63) or 3+4 = 7 ( n = 11). At initial biopsy, 23 cancers were within an MRI target, and 51 were found on systematic biopsy. Cancer detection rate on repeat biopsy (29/74, 39%) was independent of Gleason score on initial biopsy ( P = not significant) but directly related to initial cancer core length ( P <0.02). Repeat sampling of cancerous sites within MRI targets was more likely to show cancer than resampling of tumorous systematic sites (61% vs. 29%, P = 0.005). When initial cancer core length was≥4 mm within an MRI target, more than 80% (5/6) of follow-up tracking biopsies were positive. An increase of Gleason score was uncommon (9/74, 12%). Conclusions Monitoring of specific prostate cancer–containing sites may be achieved in some men using an electronic tracking system. The chances of finding tumor on repeat specific-site sampling was directly related to the length of tumor in the initial biopsy core and presence of tumor within an MRI target; upgrading of Gleason score was uncommon. Further research is required to evaluate the potential utility of site-specific biopsy tracking for patients with prostate cancer on active surveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.